Cargando…
Towards Personalized Management of Ovarian Cancer
Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60–80%, most patients will have recurrence and succumb to the disease. However, a DNA repair–directed prec...
Autores principales: | Algethami, Mashael, Kulkarni, Sanat, Sadiq, Maaz T, Tang, Hiu K C, Brownlie, Juliette, Jeyapalan, Jennie N, Mongan, Nigel P, Rakha, Emad A, Madhusudan, Srinivasan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762171/ https://www.ncbi.nlm.nih.gov/pubmed/36545222 http://dx.doi.org/10.2147/CMAR.S366681 |
Ejemplares similares
-
Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022) -
Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2022) -
Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers
por: Algethami, Mashael, et al.
Publicado: (2023) -
RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2020) -
Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
por: Alblihy, Adel, et al.
Publicado: (2021)